Home › Peripheral Arterial Disease › Ohio › Columbus
Peripheral Arterial Disease clinical trials in Columbus, OH
4 studies for Peripheral Arterial Disease are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- HNC Dialysis, Ltd., Columbus
Serranator POINT FORCE Registry
RecruitingObservational study
- Ohio State University Medical Center, Columbus
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RecruitingPhase 3
- Ohio State University Wexner Medical Center, Columbus
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
RecruitingHealthy volunteers welcome
- Nationwide Children's Hospital, Columbus
About Peripheral Arterial Disease
Peripheral arterial disease (PAD) happens when there is a narrowing of the blood vessels outside of your heart. Learn about symptoms and treatment.
More about Peripheral Arterial Disease on MedlinePlus
Peripheral Arterial Disease trials in other cities
- Chicago, IL9 studies
- Dallas, TX9 studies
- Cleveland, OH9 studies
- Boston, MA9 studies
- Houston, TX8 studies
- Gainesville, FL7 studies
- Omaha, NE7 studies
- Nashville, TN6 studies
- Aurora, CO6 studies
- Minneapolis, MN6 studies
- Miami, FL6 studies
- Norfolk, VA5 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer56 studies
- Breast Cancer39 studies
- Ovarian Cancer39 studies
- Cancer (all types)38 studies
- Lung Cancer37 studies
- Acute Myeloid Leukemia35 studies
- Chronic Lymphocytic Leukemia28 studies
- Metastatic Cancer27 studies
- Endometrial Cancer25 studies
- Colorectal Cancer24 studies
- Prostate Cancer24 studies
- Multiple Myeloma24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.